Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review
Background: Non-small-cell lung cancer (NSCLC) is recognised as a particularly heterogeneous disease, encompassing a wide spectrum of distinct molecular subtypes. With increased understanding of disease biology and mechanisms of progression, treatment of NSCLC has made remarkable progress in the pas...
Main Authors: | George Pentheroudakis, Eirini Papadopoulou, George Nasioulas, Anastasia Kougioumtzi, Panagiotis Ntellas, Eleftherios Kampletsas |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | ESMO Open |
Online Access: | https://esmoopen.bmj.com/content/4/5/e000561.full |
Similar Items
-
The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature
by: George Zarkavelis, et al.
Published: (2020-03-01) -
ALK‐rearranged squamous cell carcinoma of the lung
by: Qiyi Meng, et al.
Published: (2021-04-01) -
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-12-01) -
Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
by: Yoon Jin Cha, et al.
Published: (2014-01-01) -
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)